The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters.
Simon Bulling, Klaus Schicker, Yuan-Wei Zhang, Thomas Steinkellner, Thomas Stockner, Christian W Gruber, Stefan Boehm, Michael Freissmuth, Gary Rudnick, Harald H Sitte, Walter Sandtner
The Journal of biological chemistry May 25, 2012 DOI: 10.1074/jbc.m112.343681 via PubMed
Summary
AI-generated from the abstractIbogaine, a hallucinogenic alkaloid proposed as a treatment for opiate withdrawal, inhibits the serotonin transporter (SERT) through a noncompetitive mechanism, unlike all other known inhibitors which compete with serotonin. It binds to a distinct site accessible from the cell exterior, not the substrate-binding site, and increases accessibility in the cytoplasmic permeation pathway. Ibogaine also noncompetitively inhibits the dopamine transporter (DAT) and blocks substrate-induced currents in both transporters. The inhibition is not reversed by increasing substrate concentration, and ibogaine does not form a long-lived complex with SERT but binds directly to the inward-open conformation. A kinetic model distinguishes ibogaine's noncompetitive action from cocaine's competitive action.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Intervention | Ibogaine |
| Topics | Ibogaine |
| Keywords | Opiate withdrawal treatment Opioid addiction Substance abuse Detoxification |
| Citations | 124 |
| Key finding | Ibogaine noncompetitively inhibits serotonin and dopamine transporters by binding to a distinct external site on the inward-open conformation, unlike competitive inhibitors such as cocaine. |
Abstract
Ibogaine, a hallucinogenic alkaloid proposed as a treatment for opiate withdrawal, has been shown to inhibit serotonin transporter (SERT) noncompetitively, in contrast to all other known inhibitors, which are competitive with substrate. Ibogaine binding to SERT increases accessibility in the permeation pathway connecting the substrate-binding site with the cytoplasm. Because of the structural similarity between ibogaine and serotonin, it had been suggested that ibogaine binds to the substrate site of SERT. The results presented here show that ibogaine binds to a distinct site, accessible from the cell exterior, to inhibit both serotonin transport and serotonin-induced ionic currents. Ibogaine noncompetitively inhibited transport by both SERT and the homologous dopamine transporter (DAT). Ibogaine blocked substrate-induced currents also in DAT and increased accessibility of the DAT cytoplasmic permeation pathway. When present on the cell exterior, ibogaine inhibited SERT substrate-induced currents, but not when it was introduced into the cytoplasm through the patch electrode. Similar to noncompetitive transport inhibition, the current block was not reversed by increasing substrate concentration. The kinetics of inhibitor binding and dissociation, as determined by their effect on SERT currents, indicated that ibogaine does not inhibit by forming a long-lived complex with SERT, but rather binds directly to the transporter in an inward-open conformation. A kinetic model for transport describing the noncompetitive action of ibogaine and the competitive action of cocaine accounts well for the results of the present study.